Triple-negative breast cancer
Interviews and expert commentary tagged “Triple-negative breast cancer” — the latest oncology research and clinical practice from the Audio Journal of Oncology.
Marija Balic MD PhD, AACR 2026: Whole Exome Sequencing of ctDNA Informs Post-Neoadjuvant Therapy Options for Patients with Triple Negative Early Breast Cancer
Whole Exome Sequencing of ctDNA Informs Post-Neoadjuvant Therapy Options for Patients with Triple Negative Early Breast Cancer An interview with: Marija Balic MD PhD, Chief of Medical Breast Oncology,
Javier C Cortés MD PhD: ESMO 2025, Berlin: Initial Therapy with Sacituzumab Govitecan Improves Progression-Free Survival in Patients with Newly-Diagnosed Metastatic Triple Negative Breast Cancer—ASCENT-03 study
Javier Cortés tells his findings from ASCENT-03 as reported to ESMO 2025 in Berlin with antibody drug conjugate as initial therapy for TNBC in patients testing negative for PD-1/PD-L1
Rebecca Dent MD: ESMO Previous Highlights: Neo-Adjuvant Therapy for Triple Negative Breast Cancer, Checkpoint Inhibition, AI, Cancer Vaccines, and More ……
Rebecca Dent surveys the most recent ESMO Annual Meeting to prepare our thoughts for the ESMO 2025 meeting
Laura J. van ’t Veer PhD: Triple Negative Early Breast Cancer Genetic Sub-Types Predict No Benefit from Neoadjuvant Pembrolizumab
ImPrintTN single-sample classifier identifies no benefit from deoadjuvant pembroliozumab in TNBC
Christian Singer MD: Neoadjuvant Olaparib Combination Beats Standard of Care in Patients with Homologous Recombination Deficient BRCA 1/2-Positive Triple-Negative Breast Cancer
Homologous Repair Deficient Triple Negative Breast Cancer Positive for BRCA1/2 Mutations Better with Neoadjuvant Olaparib + Carboplatin